Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
about
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkersThe Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement.Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease.Increased CSF neurogranin concentration is specific to Alzheimer disease.Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.Plasma neuronal exosomal levels of Alzheimer's disease biomarkers in normal aging.Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profileThe Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease.Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: Implication for the screening of cognitive frailty.Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease.Plasma tau in Alzheimer disease.CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease.A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood.Synaptic proteins in CSF relate to Parkinson's disease stage markersThe use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials.Insights into the human brain proteome: Disclosing the biological meaning of protein networks in cerebrospinal fluid.Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer's disease.Biomarkers for the Early Detection and Progression of Alzheimer's Disease.Applying fluid biomarkers to Alzheimer's disease.Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke.Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer's disease, and neuronal injury in humans: a cohort study.Effect of physical exercise on markers of neuronal dysfunction in cerebrospinal fluid in patients with Alzheimer's disease.Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development.Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers.Increased expression of Myc-interacting zinc finger protein 1 in APP/PS1 mice.Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to.LPS-induced cortical kynurenic acid and neurogranin-NFAT signaling is associated with deficits in stimulus processing during Pavlovian conditioning.Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.Electroconvulsive therapy does not alter the synaptic protein neurogranin in the cerebrospinal fluid of patients with major depression.Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach.Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer's disease: an update.Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study.The Effects of Gene Mutations on Default Mode Network in Familial Alzheimer's Disease.An N-terminal motif unique to primate tau enables differential protein-protein interactions.Neurogranin as a predictor of memory and executive function decline in MCI patients.CSF neurogranin or tau distinguish typical and atypical Alzheimer disease.Association of longitudinal white matter degeneration and cerebrospinal fluid biomarkers of neurodegeneration, inflammation and Alzheimer's disease in late-middle-aged adults.Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review.
P2860
Q26745508-6ADEC6DF-C0A8-47DC-AA67-A16BF977C9ABQ31147579-2B155D9F-AE92-4DA4-9FCA-EA15B2EB6056Q36439886-CEA6A49D-367D-47B8-90F1-FE41DF8B1BFAQ36691986-2B04FEB6-E75E-4A62-A101-3E1682CA33B4Q36885492-0F2F08F6-FB85-451F-80EC-2778FE538C55Q36891744-8211ACD6-2C1A-4267-8026-7D1A79685854Q37049024-AF2673D7-841F-4373-AC36-A1D14234A328Q37169136-D1B7E5CD-E9C1-4C38-BE62-31C004676307Q37297626-86957D23-E058-4CE6-BCFF-38495464528EQ37307467-0C142E4D-A112-4C05-9DCD-BF5FDC15D922Q37384690-A08CB012-B856-48D2-826E-BCAD919505A8Q37505536-A5771234-A27E-4E74-BE55-7E3FF3F1E1D3Q38653401-747FCAAF-471D-4A3D-9EA2-860E3E294646Q38666817-8295D477-5BFE-489A-B17F-821CDE431471Q38672062-800793E2-913A-4455-B77C-315EB91F767FQ38844925-9E5C594E-8894-4D5E-8B30-7ACA41B20EC9Q38873321-32DDA8FF-CCA1-441D-BD72-58450A13E7FDQ38979999-92B3984A-22E3-40FF-B153-50C9E23D6157Q39251035-013E862E-DD16-4B17-99AF-1524ED22BE81Q41571333-E4769600-491D-4DAB-A1D0-927A7F913D4CQ42287106-97F03A1B-B046-48B3-8CF5-A9338ABCCB58Q42655670-B7ABF21C-0AD3-4640-ACE5-725B2865E2CDQ42656279-C2464CF8-EC83-4B75-8D92-53284D3B1E94Q46490492-5440A17E-02DB-43B0-989C-60FCFC6294D1Q47150841-D14C9428-B322-4A7D-9A6B-FCB88AF41B15Q47200597-33754523-6869-435E-8EB5-4F556958BAF4Q47387394-2ED809A5-5C6A-4E83-9ADF-2DF0B2917DE1Q47587631-253718B9-AF2F-49FB-ADAA-E626C123417AQ47590568-D4A84B7B-3595-4ACA-BFE4-C31960E3FEA4Q47869899-83B47B8F-2F47-4924-BB2C-A6231366E281Q47932570-337D06FA-99FB-4437-99BE-3E955F120666Q47958922-88063FC5-F4C0-4F86-9084-1BB082C6C859Q48185391-A1A3F41E-6B47-4957-ABC1-8AC3C66D9A25Q48409024-95A270CA-8060-40F6-BAAD-1DCC30393B46Q49571817-58D7F759-9B23-47C0-9B8A-C4035B27FEEEQ50048402-B71350F7-A80D-4337-866B-51C508959EDAQ50233550-1A0B40B7-F014-4984-B834-00A459EE7C98Q50591921-AFE0716C-B545-49D8-8B7E-801C64BE1F1EQ51359685-BCF588CB-E82D-483E-A7C2-3EDCB05BC551Q52585260-8EC8E60E-3566-4D87-8DF6-C10786BECE0B
P2860
Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Cerebrospinal fluid neurograni ...... ration in Alzheimer's disease.
@ast
Cerebrospinal fluid neurograni ...... ration in Alzheimer's disease.
@en
type
label
Cerebrospinal fluid neurograni ...... ration in Alzheimer's disease.
@ast
Cerebrospinal fluid neurograni ...... ration in Alzheimer's disease.
@en
prefLabel
Cerebrospinal fluid neurograni ...... ration in Alzheimer's disease.
@ast
Cerebrospinal fluid neurograni ...... ration in Alzheimer's disease.
@en
P2093
P2860
P50
P356
P1433
P1476
Cerebrospinal fluid neurograni ...... ration in Alzheimer's disease.
@en
P2093
Leslie M Shaw
Ulf Andreasson
Ulrika Törnqvist
P2860
P304
P356
10.1093/BRAIN/AWV267
P407
P50
P577
2015-09-15T00:00:00Z